最新的抗肥胖药物靶向 GLP-1 受体,胰高血糖素样肽-1 受体 (GLP1R) 是一种在胰腺 β 细胞和大脑神经元上发现的受体蛋白,它通过增强胰岛素分泌参与控制血糖水平。 胰高血糖素样肽1受体激动剂(GLP-1 receptor agonists, 简称GLP-1肽),通过增强β胰腺细胞分泌胰岛素和抑制α胰腺细胞释放胰高血糖素来改善血糖控制。
GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme
GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical ...
原文摘要 Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-p...
At equivalent doses, subcutaneous and oral semaglutide seem to have similar effects on HbA1c, body weight, and adverse events [19]. Details regarding the molecular structures of various GLP-1 RAs and additional pharmacokinetic information were summarized by Nauck and Meier in 2019 [20].The time...
(C) 10 nmol/kg/day doses. Data from equivalent dose-testing performed as part of the GEP44 (●) dose-escalation study were included in these figures to facilitate a qualitative comparison. Data shown are means ± standard error of the mean (SEM); *p < 0.05, **p < 0.01...
The extent of clearance of hepatic steatosis with ALT-801 is particularly striking in comparison to the GLP-1R only agonist, semaglutide (Fig. 3). Equivalent doses of ALT-801 and semaglutide were used throughout this study. While an approximately seven-fold higher dose of semaglutide (based ...
疟疾候选疫苗R21/Matrix-M在非洲儿童中的安全性和有效性:一项多中心、双盲、随机、Ⅲ期试验 ②The Lancet Diabetes and Endocrinology:Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial ...
1 receptor by exenatide is at least equivalent to,4 if not greater than, the degree of activation by native GLP-1, according to in vitro studies5 REFERENCES 1. DeFronzo RA, et al. Curr Med Res Opin. In press 2. Herman GA, et al. Clin Pharmacol Ther. 2005;78:675-688 3. Kolter...
An “effective amount” is that amount of a GLP-1/glucagon agonist peptide provided herein, the administration of which to a subject, either in a single dose or as part of a series, is effective for treatment, e.g., treatment of obesity. An amount is effective, for example, when its ...